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Esophageal cancer rarely coincides with pregnancy, and only five cases have been reported thus far.Themanagement of esophageal
cancer during pregnancy is extremely challenging due to its aggressive nature. We herein report a case of recurrent esophageal
cancer in pregnancy. A 41-year-old multigravida with a history of esophageal squamous cell cancer treated with esophagectomy
and perioperative chemotherapy was diagnosed with local recurrent carcinoma of the residual esophagus at 16 weeks of gestation.
The patient strongly desired to continue the pregnancy, and concurrent chemoradiation therapy (CRT) consisting of 50.4 Gy
of radiation, cisplatin, and 5-fluorouracil was carried out from 19 weeks of gestation. CRT was dramatically effective, and the
recurrent lesion disappeared. At 38 weeks of gestation, she underwent cesarean section and delivered a healthy female baby. Both
maternal and fetal courses were satisfactory, and the patient has been free of disease for 12 months.This is the first case of recurrent
esophageal cancer in pregnancy in which CRT was completed without reducing treatment intensity and led to a complete response.
Nevertheless, little is known regarding the safety and possible adverse effects of CRT on the fetus. Therefore, deliberate selection of
patients and long-term follow-up of the child are necessary.
1. Introduction
With increasing maternal age and improvements in diag-
nostic techniques, the incidence of cancer in pregnancy
has risen to one in 1,000 pregnancies [1], and it is not
necessarily a rare entity. However, esophageal cancer com-
plicated with pregnancy is extremely uncommon. Thus, its
management strategy has not yet been discussed thoroughly.
Here, we describe a case of recurrent esophageal cancer
treated successfully with concurrent chemoradiation therapy
(CRT) during pregnancy. Further, we also review previously
reported cases of esophageal cancer in pregnancy.
2. Case Report
A 41-year-old woman, gravida 2, para 1, was diagnosed
with esophageal cancer relapse at 16 weeks of gestation.
At the age of 40, before this spontaneous conception,
she underwent preoperative chemotherapy, minimally inva-
sive esophagectomy, and postoperative chemotherapy for
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Figure 1: The gastrointestinal endoscopic finding at 16 weeks of
gestation. Arrowheads indicate the recurrent lesion of esophageal
cancer in the residual esophagus.
esophageal squamous cell cancer, cStageII, pStageIV. Since
the postoperative chemotherapy, she had been amenorrhoeic.
Tenmonths after the operation, contrast enhanced computed
tomography (CT) of the neck, chest, and abdominal to
pelvis region was performed to investigate recurrence or
metastasis, and it showed a pregnant uterus. She visited
our obstetric clinic and was confirmed to be at 8 weeks of
gestation. Because the estimated fetal exposure dose of the
CT examination was less than 8 mGy, she wished to continue
the pregnancy. At 16 weeks of gestation, the scheduled
gastrointestinal endoscopy and biopsy revealed relapse of
esophageal cancer in the residual esophagus (Figure 1). The
fluorine-18 fluorodeoxyglucose (18F-FDG) uptake of the local
recurrence in the residual esophagus was elevated accord-
ing to positron emission tomography (PET)/CT, and no
metastatic lesion was detected. Amultidisciplinary treatment
team consisting ofmedical oncologists, radiation oncologists,
surgeons, and obstetricians recommended that the patient
terminate the pregnancy and receive CRT, which was the
standard treatment for localized recurrent disease [2, 3].
However, the patient and her husband strongly desired to
continue the pregnancy.
To examine the safety and feasibility of radiotherapy for
this patient, the fetal dose was estimated by a simulation
study before CRT. We created the irradiation plan for the
patient (Figure 2(a)) and delivered doses to the phantom
(Figure 2(b)). According to the radiation dosage measured
by five dosimeters, which ranged from 0.052 to 0.176 mGy
in one irradiation fraction (Figure 2(c)), the fetal dose was
estimated as 1.56 to 5.28 mGy, even after 60 Gy in 30
fractions of radiotherapy. The anticancer drugs, which would
be administered together with the radiation, were cisplatin
(CDDP) and 5-fluorouracil (5-FU). Taking these results, we
concluded that CRT during pregnancy in this case would
be acceptable and, after receiving written informed consent,
started the treatment at 19 weeks of gestation.
The CRT consisted of 50.4 Gy in 28 fractions of radiation
and four courses of chemotherapy (CDDP 60 mg/m2 on day
1, 5-FU 750 mg/m2 on days 1 to 4). Figure 3 shows the course
of treatment over time. As supportive therapy, palonosetron
and dexamethasone were administered. To assess the actual
fetal dose of radiotherapy, we put dosimeters on the patient’s
abdomen at every irradiation session. Dosimeters showed
that the estimated fetal dose ranged from 0.08 to 0.34mGy in
one irradiation fraction. Consequently, the multidisciplinary
team confirmed the safety and feasibility of radiotherapy for
this pregnant patient and fetus and completed the planned
radiotherapy. After chemoradiotherapy, at 27 weeks of gesta-
tion, the recurrent lesion was decreased in size. Furthermore,
gastrointestinal endoscopy at 31 weeks did not detect the
recurrent lesion after the third course of chemotherapy.
During this treatment, the myelosuppression wasmild; grade
2 anemia, grade 1 neutrophil count decreased, and grade 1
platelet count decreased, according toCommonTerminology
Criteria for Adverse Events (CTCAE)Version 5.0.The patient
had also pharyngitis, anorexia, and vomiting. Regarding body
habitus, her height was 162 cm, and her weight was 51 kg
before the esophagectomy. Then she had lost 6 kg and her
body mass index was 17.5 by the time she got pregnant. Her
weight gain was only 3.9 kg during pregnancy because of
impaired oral intake due to gastric tube reconstruction as
well as adverse effect of CRT such as anorexia. The fetal
estimated body weight fluctuated between the 10th and 20th
percentile. Fetal well-being was monitored using ultrasound
and nonstress fetal heart rate testing, and no abnormal
findings were detected. At 38 weeks and 3 days of gestation,
she underwent cesarean section (due to previous cesarean
section) and gave birth to a female baby weighing 2,480 g.
Apgar scoreswere 7 at 1minute and 8 at 5minutes, and the pH
of umbilical artery blood was 7.327.The baby did not have any
congenital anomalies, and the clinical course was uneventful.
Twelve months have passed since the cesarean section, the
patient has been free of disease, and the growth of the infant
has been satisfactory.
3. Discussion
Esophageal cancer in pregnancy is extremely rare, because
esophageal cancer occurs mainly in males in their sixties
and seventies. There have been only five cases of esophageal
cancer in pregnancy [4–8] thus far, as shown in Table 1.
Four caseswere primary esophageal cancer diagnosed in toon
average, and the initial symptom was dysphagia in all cases.
The prognosis of these cases was poor due to the aggressive
nature of esophageal cancer. In the present case, however,
recurrence was detected early as the localized disease by
our regular trimonthly follow-up, and both maternal and
fetal outcomes were favorable, while the median survival
duration of the patients with recurrent disease after radical
esophagectomy is 5 to 10 months [9].
When cancer is detected in pregnancy, especially before
22 weeks of gestation, both the patient and physicians are
caught in a dilemma of whether to continue or terminate
the pregnancy. In general, therapeutic strategies for cancer
in pregnancy should adhere to the standard for nonpregnant
patients, and treatment intensity should not be reduced to
guard against potential adverse effects to the fetus. In the
present case, because the patient and her husband strongly
wished to continue the pregnancy, the multidisciplinary team















Figure 2: The simulation study of radiotherapy using a phantom. (a) The irradiation plan was created based on the recurrent lesion. The
distance between the inferior margin of irradiation and the uterine fundus was 38 cm. (b) Five dosimeters (arrows) were put on the phantom’s
abdomen. (c)The radiation dosage measured by five dosimeters in one irradiation fraction.
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Figure 3: The time course of treatment. The horizontal axis indicates gestational weeks. CF, cisplatin 60 mg/m2, 5-fluorouracil 750 mg/m2;
CS, cesarean section.
assessed the feasibility of treatment during pregnancy. In
order to permit the pregnancy continuation, it is essential to
confirm no metastasis, and the patient underwent PET/CT.
A full PET/CT scan is thought to deliver no greater than 15-
20 mGy, and the placenta concentrates 0.19-0.27% of injected
activity of 18F-FDG [10, 11]. In general, the dose of 18F-FDG
and radiation is reduced as much as possible for pregnant
women to lessen fetal exposure. Indeed, in the present case,
the estimated maternal radiation dosage by PET/CT was
calculated to be 3.8 mSv; PET 2.1 mSv, and CT 1.7 mSv, which
was approximately equal to 3.8 mGy. Accordingly, PET/CT
during pregnancy might be allowed, given that PET/CT plays
a pivotal role in diagnosis and surveillance of metastatic
lesions.
It is acknowledged that cancer chemotherapy is possible
after 12 to 14 weeks of gestation, which is the period of
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organogenesis [12]. Cisplatin and fluorouracil are key drugs
for chemotherapy in esophageal cancer [13, 14], and both have
a relatively extensive history of use in pregnant patients from
the second trimester onward. Mir et al. reported that, among
36 patients receiving cisplatin, one case of polyhydramnios,
two cases of oligohydramnios, and three cases of fetal growth
restrictionwere detected, although the causative link between
cisplatin administration and these malformations remains
speculative [15]. For 5-fluorouracil, one cohort study includ-
ing 57 breast cancer patients receiving 5-fluorouracil during
the second and third trimesters of pregnancy described three
cases of congenital disease, including trisomy 21, club foot,
and bilateral ureteral reflux [16]. The causal relationship
between these diseases and 5-fluorouracil is unknown.
In our case, the newborn was relatively small at 2,480
g (13.2 percentile), although she was not regarded as small-
for-gestational-age (SGA). It remains inconclusive whether
cancer chemotherapy or cancer per se in pregnancy affects
fetal growth. Cardonick et al. analyzed 376 fetuses exposed
to chemotherapy in utero and reported that the incidence
of fetal growth restriction was 7%, which might be as
low as that in the normal population [17]. However, Van
Calsteren et al. showed that SGA was observed significantly
more often (16/66, 24.2%) in cancer patients given cytotoxic
treatment [18]. Presumably, in the present case, CRT-induced
pharyngitis and anorexia caused poor maternal weight gain
during pregnancy, thereby contributing to the relatively light
body weight of the newborn.
Meanwhile, radiotherapy during pregnancy could also
be acceptable when the irradiation area is remote from the
pelvis; several kinds of malignancies, such as breast cancer,
Hodgkin’s disease, brain tumors, and head and neck cancer,
are treated with radiation therapy during pregnancy [19].
However, careful planning and calculation of the fetal dose
using a phantom before treatment are necessary in order
to assess the risk of radiation to the fetus. To evaluate and
estimate the fetal dose, the Monte Carlo method can be
employed. Bednarz and Xu demonstrated the computational
procedure which could determine the absorbed organ dose
in the mother and fetus, using realistic models of pregnant
women during 3-, 6-, and 9-month gestational age [20].
In the current case, fetal dose was estimated at most 5.28
mGy even after 60 Gy in 30 fractions of radiotherapy. It was
under the threshold dose for deterministic effects (50 mGy)
regarding radiation injury to an unborn fetus [21]. Although
the number of cases of chemotherapy and radiotherapy in
pregnancy has been accumulating, CRT during pregnancy
is still rare. To our knowledge, there has been no systematic
review or cohort study verifying the adverse effects of CRT
in pregnancy on the unborn fetus. Only in the fields of
tongue cancer and Hodgkin’s disease have a few cases of CRT
in pregnancy been reported, and its influence on babies is
currently unknown [22–24].
In summary, this is the first case of recurrent esophageal
cancer in pregnancy in which CRT was completed without
reducing treatment intensity and led to a complete response.
Moreover, severe perinatal complications were not detected,
and both the maternal and fetal courses were satisfactory.
Our case suggests that CRT based on careful simulation could
be an effective alternative treatment strategy for recurrent
esophageal cancer in pregnancy. Nevertheless, little is known
in terms of the safety and possible adverse effects of CRT on
the fetus.Therefore, deliberate selection of patients and long-
term follow-up of the child are necessary.
Consent
Written informed consent was obtained from the patient
for the publication of this case report and its accompanying
images.
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